New Slow-Release pyridostigmine pill tested for easier dosing
NCT ID NCT07154095
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 30 times
Summary
This study tested a new sustained-release (slow-release) tablet of pyridostigmine, a drug used to treat myasthenia gravis, against the standard immediate-release tablet. Forty healthy Chinese volunteers took both versions in random order, separated by a washout period. Researchers measured drug levels in the blood and monitored safety. The goal was to see if the new tablet provides a more convenient dosing option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
West China Second University Hospital
Chengdu, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pyridostigmine
What this could lead to
If successful, this could lead to a once-daily version of pyridostigmine that is easier for people with myasthenia gravis to take, with fewer doses needed each day.
What could go wrong
This is a very early Phase 1 study in only 40 healthy people, not patients. It only checks drug levels and safety, not whether the new tablet actually improves symptoms.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.